Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Positive interim results for AG-858/Gleevec combination therapy in CML

Dec. 20, 2002

Epratuzumab safe and effective in non-Hodgkin's lymphoma

Dec. 20, 2002

Phase I clinical testing commences for two Igeneon cancer products

Dec. 20, 2002

HER-2 DNA AutoVac therapeutic vaccine safe and immunogenic in breast cancer patients

Dec. 19, 2002

Modified dosing schedule of apolizumab allows higher doses in CLL and ALL

Dec. 19, 2002

Trifunctional bispecific antibody shows potential for B-cell lymphoma

Dec. 18, 2002

TP-38 demonstrates antitumor activity in glioblastoma

Dec. 17, 2002

Potential use of CC-5013 in the treatment of hematological malignancies

Dec. 17, 2002

Disappointing phase III preliminary results for CeaVac in colorectal cancer

Dec. 16, 2002

IDEC-114 reported safe and effective in refractory follicular lymphoma

Dec. 16, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...